BACKGROUND: Caspase-8 (CASP8) and caspase-9 (CASP9) play crucial roles in regulating apoptosis, and their functional polymorphisms may alter cancer risk. Our aim was to investigate the association of CASP8 and CASP9 gene polymorphisms with gastric cancer (GC) susceptibility. METHODS: We undertook a case-control study of 88 GC cases and 480 controls to investigate the association between CASP8 -652 6N ins/del and CASP9 -1263 A>G polymorphisms and GC susceptibility by a polymerase chain reaction (PCR)-restriction fragment length polymorphism method. RESULTS: CASP8 -652 6N ins/del polymorphism and CASP9 -1263 GG genotype were observed to be significantly associated with a reduced risk of GC. No significant association was observed between CASP8 -652 6N ins/del and CASP9 -1263 A>G polymorphisms and tumor characteristics. However, both CASP8 del/del and CASP9 -1263 GG genotypes were associated with increased overall survival in GC patients. CONCLUSIONS: The CASP8 -652 6N ins/del and the CASP9 -1263 A>G polymorphisms were observed to play a protective role in GC predisposition.
BACKGROUND:Caspase-8 (CASP8) and caspase-9 (CASP9) play crucial roles in regulating apoptosis, and their functional polymorphisms may alter cancer risk. Our aim was to investigate the association of CASP8 and CASP9 gene polymorphisms with gastric cancer (GC) susceptibility. METHODS: We undertook a case-control study of 88 GC cases and 480 controls to investigate the association between CASP8-652 6N ins/del and CASP9 -1263 A>G polymorphisms and GC susceptibility by a polymerase chain reaction (PCR)-restriction fragment length polymorphism method. RESULTS:CASP8-652 6N ins/del polymorphism and CASP9 -1263 GG genotype were observed to be significantly associated with a reduced risk of GC. No significant association was observed between CASP8-652 6N ins/del and CASP9 -1263 A>G polymorphisms and tumor characteristics. However, both CASP8 del/del and CASP9 -1263 GG genotypes were associated with increased overall survival in GC patients. CONCLUSIONS: The CASP8-652 6N ins/del and the CASP9 -1263 A>G polymorphisms were observed to play a protective role in GC predisposition.
Authors: Wei Wang; Margaret R Spitz; Hushan Yang; Charles Lu; David J Stewart; Xifeng Wu Journal: Clin Cancer Res Date: 2007-10-01 Impact factor: 12.531
Authors: Christopher A Haiman; Rachel R Garcia; Laurence N Kolonel; Brian E Henderson; Anna H Wu; Loïc Le Marchand Journal: Nat Genet Date: 2008-03 Impact factor: 38.330
Authors: Eswaran Devarajan; Aysegul A Sahin; Jack S Chen; Raghu R Krishnamurthy; Neeraj Aggarwal; Anne-Marie Brun; Anna Sapino; Fan Zhang; Dhawal Sharma; Xiao-He Yang; Ann D Tora; Kapil Mehta Journal: Oncogene Date: 2002-12-12 Impact factor: 9.867
Authors: Jae Yong Park; Jung Min Park; Jin Sung Jang; Jin Eun Choi; Kyung Mee Kim; Sung Ick Cha; Chang Ho Kim; Young Mo Kang; Won Kee Lee; Sin Kam; Rang Woon Park; In San Kim; Jae-Tae Lee; Tae Hoon Jung Journal: Hum Mol Genet Date: 2006-05-10 Impact factor: 6.150
Authors: Young Hwa Soung; Jong Woo Lee; Su Young Kim; Won Sang Park; Suk Woo Nam; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee Journal: APMIS Date: 2006-04 Impact factor: 3.205
Authors: Matthew L Freedman; Kathryn L Penney; Daniel O Stram; Loïc Le Marchand; Joel N Hirschhorn; Laurence N Kolonel; David Altshuler; Brian E Henderson; Christopher A Haiman Journal: Hum Mol Genet Date: 2004-08-18 Impact factor: 6.150
Authors: Ana P Azevedo; Susana N Silva; Alice Reichert; Fernando Lima; Esmeraldina Júnior; José Rueff Journal: Pathol Oncol Res Date: 2018-03-14 Impact factor: 3.201
Authors: Peter M Waziri; Rasedee Abdullah; Swee Keong Yeap; Abdul Rahman Omar; Nur Kartinee Kassim; Ibrahim Malami; Chee Wun How; Imaobong Christopher Etti; Mary Ladidi Abu Journal: BMC Complement Altern Med Date: 2016-07-29 Impact factor: 3.659